Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.50 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7836979 | 0.81 | CTSS (0.54) | CTSSCTSKSYKSERPINE1OPRM1 | |
| SCHEMBL17592938 | 0.81 | CTSS (0.49) | CTSSCTSKSYKSERPINE1PPARG | |
| SCHEMBL22153160 | 0.80 | CTSS (0.53) | CTSSCTSKSYKOPRM1 | |
| SCHEMBL13960420 | 0.80 | OPRM1 (0.40) | CTSSCTSKPPARAOPRM1MIF | |
| SCHEMBL29333309 | 0.79 | ATM (0.60) | CTSSCTSKSYKPPARAOPRM1 | |
| SCHEMBL20805990 | 0.78 | CTSS (0.51) | CTSSCTSKSYKSERPINE1OPRM1 | |
| SCHEMBL23328949 | 0.76 | CTSS (0.52) | CTSSCTSKPPARGPPARAATM | |
| SCHEMBL506202 | 0.74 | GAA (0.57) | CTSSCTSKMIFGAANQO2 | |
| SCHEMBL12667207 | 0.73 | ADRB2 (0.42) | CTSSCTSKSYKSERPINE1PPARG | |
| SCHEMBL507975 | 0.73 | GAA (0.56) | CTSSCTSKMIFGAANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | CTSS 3511/4885CTSK 813/4885SYK 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.